AstraZeneca Results Presentation Deck
CEO Opening Remarks
P
Oncology - R&D highlights
Eight positive pivotal trial readouts so far this year
ASCO highlights 2023
ADAURA final overall survival
unprecedented survival in EGFRm NSCLC with
88% of patients alive on Tagrisso at 5 years
Financial Results
DUO-O interim analysis
37% reduction in risk of progression or death
with Lynparza and Imfinzi added to
chemotherapy and bevacizumab
DESTINY-PanTumor02 interim analysis
37% ORR and 11.8 month mDoR with Enhertu
across range of HER2-expressing solid tumours
FLAURA2
R
1:1
R
Oncology
1:1
DUO-E advanced endometrial cancer
Platinum CTX + Imfinzi placebo
Platinum CTX+ Imfinzi
Platinum CTX+ Imfinzi
R
1:1
1L EGFRm advanced NSCLC
BioPharmaceuticals
Tagrisso
Tagrisso + carbo/cis + pemetrexed
Placebo + FLOT
Imfinzi + FLOT
MATTERHORN resectable gastric and GEJ cancers
SURGERY
Rare Disease
Placebo + FLOT
Imfinzi + FLOT
Presidential plenary WCLC)
Imfinzi placebo + Lynparza placebo
Imfinzi + Lynparza placebo
Imfinzi + Lynparza
CEO Closing Remarks
Tagrisso
Tagrisso + pemetrexed
ASCO = American Society of Clinical Oncology; EGFRm = epidermal growth factor receptor mutated; NSCLC = non-small cell lung cancer; ORR = objective response rate; mDoR = median duration of response; HER2 = human epidermal
17 growth factor receptor 2; 1L = 1st-line; R = randomise; carbo/cis = carboplatin/cisplatin; CTX = chemotherapy; GEJ = gastroesophageal junction; FLOT = fluorouracil, leucovorin, oxaliplatin and docetaxel.
Collaboration partners: Daiichi Sankyo (Enhertu)
Placebo
ImfinziView entire presentation